Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension

Inclusion Criteria: * Participants must be 18 years of age or older. All genders are eligible; * Confirmed diagnosis of Chronic Kidney Disease (CKD) according to KDIGO. guidelines; * UACR \< 30 mg/g (3.4 mg/mmol) and eGFR between 20-44 mL/min/1.73 m²; or UACR between 30-300 mg/g (3.4-33.9 mg/mmol) and eGFR between 20-59 mL/min/1.73 m²; or UACR between 300-5000 mg/g (33.9-565 mg/mmol) and eGFR \> 20 mL/min/1.73 m² (CKD-EPI equation). * Office blood pressure measurements below 140/90 mmHg at both screening visits; * Daytime ambulatory blood pressure \< 135/85 mmHg and nighttime systolic blood pressure ≥ 120 mmHg or diastolic blood pressure ≥ 70 mmHg; * No use of corticosteroids, immunosuppressants, or biologic agents for at least one month prior to enrollment; Exclusion Criteria: * Presence of acute kidney injury or acute renal failure; * History of kidney transplantation; * Presence of severe arrhythmias, including severe atrial fibrillation, atrioventricular (AV) block, sinoatrial (SA) block, sinus bradycardia, malignant AV node reentrant tachycardia syndrome; * Secondary hypertension related to suspected or confirmed renal artery stenosis or adrenal gland disorders; * Poor glycemic control (HbA1c \> 12%); * Orthostatic hypotension (a decrease in blood pressure of \>20/10 mmHg within 3 minutes of standing from a sitting position); * Women who are pregnant or breastfeeding at the time of enrollment, or not employing contraception of reproductive age; * NYHA (New York Heart Association) Class III-IV congestive heart failure at the time of enrollment; * History of myocardial infarction, unstable angina, acute heart failure, stroke, transient ischemic attack (TIA), or cerebral hemorrhage within the 12 weeks prior to enrollment; * Underwent coronary revascularization (Percutaneous Coronary Intervention \[PCI\] or Coronary Artery Bypass Grafting \[CABG\]), or valve repair/replacement within the 12 weeks prior to enrollment, or planned to undergo any of the aforementioned surgical procedures after randomization; * Any other serious diseases outside the renal and cardiovascular domains, including but not limited to malignancies, with an expected survival of less than 2 years based on the investigator's clinical judgment; * Presence of active malignancy requiring pharmacological treatment; * AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) levels \>3 times the upper limit of normal (ULN); * Total bilirubin \>2 times ULN. Patients with Gilbert's syndrome who exhibit isolated bilirubin elevation do not need to be excluded;